NCT02227303已完成不适用
A Pilot Open Label Clinical Trial to Evaluate the Combined Impact of Two Mobile Health Products on Health Outcomes in Overweight Adults With Type 2 Diabetes
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 2
- 主要终点
- Changes from baseline to 8 weeks in glucose, insulin, fructosamine and HgbA1c
研究概览
简要总结
The purpose of this study is to explore the effect of 8-weeks use of the Medidata Patient Cloud (a mobile application for capturing data directly from subjects, enabling entry of diary and quality of life data into internet-enabled devices) in combination with an activity tracker (Fitbit Flex) on health outcomes in overweight people with Type 2 Diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects, aged 18 to 60 years, who are English or Spanish speakers.
- •BMI 25 to 34.9 kg/m2
- •Subject has type 2 diabetes with HgbA1c < 8.0%
- •Subject's glucose is controlled with either diet alone or oral agents that do not cause hypoglycemia (e.g. Metformin, DPP-4 inhibitors, Thiazolidinediones, Alpha-Glucosidase Inhibitors and GLP-1 agonists).
- •Subject is motivated to increase their activity and make other lifestyle changes.
- •Subject has:
- •A compatible Apple mobile device with the iOS 7 operating system installed:
- •iPhone 4 or newer
- •iPad 2 or newer
- •iPad Mini
- •iPod touch 5th gen (2012 model) or newer
- •500MB of free space on the iPhone, iPad, or iPod touch
- •A valid mobile phone number to receive daily updates via SMS text messaging
- •An active iTunes account/password to install study-related software ("apps")
- •Access to Wi-Fi or a mobile data plan to send study data
- •Female subject is surgically sterile, post-menopausal or agrees to use an acceptable method of birth control as defined in section 2.
- •Subject agrees to not use any new vitamin and/or mineral supplement until after study completion.
- •Subject agrees to not take any dietary or herbal supplements or products until after study completion. Seven-day washout period prior to study inclusion allowed.
- •Subject is willing and able to comply with the protocol including:
- •Attending 3 visits, approximately 2 hours each
- •Wearing and inputting required information into the Fitbit Flex activity tracker
- •Receiving alerts from the Medidata Patient Cloud
- •Working on making nutrition and exercise changes over the 8-week study period
- •Using and updating his/her iPhone, iPad, iPad Mini or iTouch as per study requirements (e.g. downloading the iOS7 operating system, downloading the Medidata Patient Cloud and Fitbit Flex apps, and receiving daily text messages).
- •Subject is able to understand and sign the informed consent to participate in the study.
排除标准
- •Subject has any of the following medical conditions:
- •active heart disease
- •uncontrolled high blood pressure (≥ 140/90 mmHg)
- •renal or hepatic impairment/disease
- •Type I diabetes
- •bipolar disorder
- •active psychiatric disease
- •Parkinson's disease
- •unstable thyroid disease
- •immune disorder (such as HIV/AIDS)
- •any medical condition deemed exclusionary by the Principal Investigator (PI)
- •Subject has a history of cancer (except localized skin cancer without metastases or in situ cervical cancer) within five years prior to screening.
- •Subject is taking oral agents that can cause hypoglycemia (e.g. sulfonylureas, meglitinides and insulin).
- •Subject is taking or has taken in the past 28 days any supplement or medication (prescription or over the counter) for weight loss (see section 2.6.2); 28-day washout required for study inclusion.
- •Subject is on an unstable dose of medication (defined as fewer than 90 days at the same dose).
- •Subject is currently taking any medication deemed exclusionary by PI.
- •Subject exhibits evidence of hepatic or renal dysfunction as evidenced by ALT, AST, AP being ≥ 2 times the upper limit of normal or serum creatinine value ≥ 2.0 mg/dl or other clinically significant abnormal clinical laboratory value per PI discretion.
- •Subject has a clinically relevant abnormality as defined by the PI or interpreting physician with respect to the electrocardiogram (ECG).
- •Subject has a QTc interval > 450 msec for males and > 470 msec for females.
- •Subject has a history of drug or alcohol abuse in the past 12 months.
- •Subject has begun/stopped smoking ≤ 6 months ago OR has plans to begin/quit smoking.
- •Subject has experienced a weight loss or gain greater than 4.5 kg (approximately 10 lbs) in the past 3 months.
- •Subject is pregnant, lactating, or planning to become pregnant during the study period.
- •Subject has any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the subject or the quality of the study data.
- •Subject has taken an investigational product within 30 days of study enrollment (visit 2).
结局指标
主要结局
Changes from baseline to 8 weeks in glucose, insulin, fructosamine and HgbA1c
时间窗: 8 weeks
Changes from baseline to 4 and 8 weeks in body weight.
时间窗: 4 to 8 weeks
Changes from baseline to 4 and 8 weeks in compliance with nutrition goals as measured via dichotomous questionnaire.
时间窗: 4 to 8 weeks
Weekly changes over 8 weeks as compared to baseline in quality of life as measured by the PROMIS® Global Health questionnaire (global physical health and global mental health subscale scores and social and overall health scores).
时间窗: 8 weeks
Changes from baseline to 4 and 8 weeks in compliance with exercise goals as measured by steps per day (provided by the Fitbit Flex).
时间窗: 4 to 8 weeks
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Effectiveness and Safety of a Digitally Based Multidomain Intervention for Mild Cognitive ImpairmentMild Cognitive ImpairmentNCT05059353Neuroglee Therapeutics55
终止
不适用
Electronic Patient Reported Outcomes in Measuring Health-Related Quality of Life in Patients With Stage I-IV Prostate Cancer Undergoing TreatmentProstateNCT03197948Sidney Kimmel Cancer Center at Thomas Jefferson University20
终止
2 期
Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With FulvestrantAdvanced Breast CancerNCT04862143Novartis Pharmaceuticals2
已完成
不适用
Effects of a Digital Patient Platform (CMyLife) for Patients With Chronic Myeloid Leukemia (CML) on Information Provision, Patient Empowerment, Medication Compliance, Guideline Adherence and Quality of LifeNeoplasmsChronic Myeloid LeukemiaPatient PortalsTelemedicineNCT04595955Radboud University Medical Center99
已完成
不适用
Clinical Study to Compare Two Skin Substitute Categories for Their Effectiveness to Treat Diabetic Foot UlcersDiabetic Foot UlcerNCT06557122Encoll Corp24